Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
Clinical trial NCT04799249 · COMPLETED
Trial details
- NCT number
- NCT04799249
- Sponsor
- G1 Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-14
- Primary completion
- 2024-05-24
- Enrollment
- 194
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.